As of 2026-09-23, the Relative Valuation of Cymabay Therapeutics Inc (CBAY) is (11.89) USD. This relative valuation is based on P/E multiples. With the latest stock price at 32.48 USD, the upside of Cymabay Therapeutics Inc based on Relative Valuation is -136.6%.
The range of the Relative Valuation is (7.69) - (16.25) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 20.5x | 12.7x |
| Forward P/E multiples | 8.4x - 17.7x | 13.2x |
| Fair Price | (7.69) - (16.25) | (11.89) |
| Upside | -123.7% - -150.0% | -136.6% |
| Date | P/E |